Gilead finds CAR-T manufacturing costly but says Kite’s is ‘superb’ and cost-efficient – FiercePharma
FiercePharma |
Gilead finds CAR–T manufacturing costly but says Kite's is 'superb' and cost-efficient
FiercePharma Gilead Sciences is betting nearly $12 billion on Kite Pharma's CAR–T technology, and one of the factors that influenced it is Kite's readiness to handle the complex and time-sensitive manufacturing and logistics demanded by the personalized cell … Bio Roundup: CAR–T's Huge Week, Merck's 'Pib Choice & More Gilead's Acquisition Of Kite Pharma Relieves Shareholders' Ennui |
